StevenJKuerbitzMD

Pediatric Hematology & Oncology • Akron, OH

Professor, Pediatrics, Northeastern Ohio Medical Univ

Join to view full profile

Dr. Kuerbitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kuerbitz's full profile

Already have an account?

Office
1 Perkins Sq
Akron, OH 44308
Phone+1 330-543-8730

Fax+1 330-543-3836
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Indiana University School of MedicineResidency, Pediatrics, 1984 - 1988
Wayne State University School of MedicineClass of 1984

Certifications & Licensure

OH State Medical License 1995 - 2024
MD State Medical License 1988 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
Completed
Phase 3
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Start of enrollment: 2014 Mar 05
Recruiting
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Start of enrollment: 2013 Dec 24
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29
Recruiting
Phase 3
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

6 citations
Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.
Haleema Saeed, Sayantani Sinha, Christine Mella, Jeffrey S Kuerbitz, Monica L Cales, Mark A Steele, Jennifer Stanke, Derek S. Damron, Fayez F. Safadi, Steven J Kuerbitz> ;Oncotarget. 2020 May 19
1 citations
WT1 regulates cyclin A1 expression in K562 cells.
Sony Pandey, Mustafa Moazam, Nirmala Ghimirey, Steven J. Kuerbitz, Gail Fraizer> ;Oncology Reports. 2019 Nov 1
21 citations
An Unusual Form of Superficially Disseminated Glioma in Children: Report of 3 Cases
Dimitri P. Agamanolis, Christos D. Katsetos, Christopher J. Klonk, Henry M. Bartkowski, Srinivas Ganapathy, Susan M. Staugaitis, Steven J. Kuerbitz, Donna F. Patton, A...> ;Journal of Child Neurology. 2012 Jun 1
13 citations
Three Children with CD30+ Cutaneous Anaplastic Large Cell Lymphomas Bearing the t(2;5)(p23;q35) Translocation
Molly Hinshaw, Andrea B. Trowers, Eric Kodish, Steven Kuerbitz, Susan Shurin, Gary S. Wood> ;Pediatric Dermatology. 2004 May 1
46 citations
Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia
Steven J. Kuerbitz, Joshua M. Pahys, Alison Wilson, Nicole Compitello, Todd A. Gray> ;Carcinogenesis. 2002 Apr 1
251 citations
Transcriptional Silencing of the p73 Gene in Acute Lymphoblastic Leukemia and Burkitt’s Lymphoma Is Associated with 5′ CpG Island Methylation
Paul G. Corn, Steven J. Kuerbitz, Max M. van Noesel, Manel Esteller, Nicole Compitello, Stephen B. Baylin, James G. Herman> ;Cancer Research. 1999 Jul 15
6 citations
Deletion of p16INK4A/CDKN2 and p15INK4B in human somatic cell hybrids and hybrid-derived tumors
Steven J. Kuerbitz, Jennifer Malandro, Nicole Compitello, Stephen B. Baylin, Jeremy R. Graff> ;Cell Growth & Differentiation. 1999 Jan 1
8 citations
Retention of unmethylated CpG island alleles in human diploid fibroblast x fibrosarcoma hybrids expressing high levels of DNA methyltransferase
Steven J. Kuerbitz, Stephen B. Baylin> ;Cell Growth & Differentiation. 1996 Jun 1
366 citations
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.
Michele Makos Wales, Margaret A. Biel, Wafik El Deiry, Barry D. Nelkin, Jean Pierre J. Issa, Webster K. Cavenee, Steven J. Kuerbitz, Stephen B. Baylin> ;Nature Medicine. 1995 Jun 1
47 citations
Control of G1 arrest after DNA damage.
Michael B. Kastan, Steven J. Kuerbitz> ;Environmental Health Perspectives. 1993 Dec 1
49 citations
Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study.
Steven J. Kuerbitz, Curt I. Civin, Jeffrey P. Krischer, Yaddanapudi Ravindranath, C. P. Steuber, Howard J. Weinstein, Naomi J. Winick, A. H. Ragab, M V Gresik, W M Crist> ;Journal of Clinical Oncology. 1992 Sep 1
1493 citations
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Steven J. Kuerbitz, Beverly Plunkett, William V. Walsh, Michael B. Kastan> ;Proceedings of the National Academy of Sciences of the United States of America. 1992 Aug 15
162 citations
Levels of p53 protein increase with maturation in human hematopoietic cells.
Michael B. Kastan, Arthur I. Radin, Steven J. Kuerbitz, Onyinye Onyekwere, Cathy A. Wolkow, Curt I. Civin, Kelly D. Stone, Tom Woo, Yaddanapudi Ravindranath, Ruth W. C...> ;Cancer Research. 1991 Aug 15
Join now to see all

Grant Support

Regional Hypermethylation In HematopoiesisNational Cancer Institute1995–1996
Regional Hypermethylation In HematopoiesisNational Cancer Institute1994–1995
Regional Hypermethylation In Human HematopoiesisNational Cancer Institute1992–1993

Hospital Affiliations

Akron Children's HospitalAkron, Ohio

StevenJKuerbitzMD

Dr. Kuerbitz is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.